Preoperative evaluation of pancreatic adenocarcinoma

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 15, Issue 4, 2008, Pages 429-435

  Parsons, Colin M ^a   Sutcliffe, Julie L ^b   Bold, Richard J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pancreatic cancer; PET scan; Preoperative imaging; Tumor markers

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MODEL; HUMAN; METASTASIS; MOLECULAR IMAGING; MORBIDITY; NONHUMAN; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION;

ADENOCARCINOMA; CA-19-9 ANTIGEN; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE-6-PHOSPHATE; HUMANS; INTEGRIN ALPHAV; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 48749093921     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-007-1240-7     Document Type: Article

References (72)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol 2003;30(4 Suppl 11):3-10.
3. Ellsmere J, Mortele K, Sahani D, et al. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma? Surg Endosc 2005;19:369-373.
4. Gulliver DJ, Baker ME, Cheng CA, et al. Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. AJR Am J Roentgenol 1992;159:503-507.
5. Prokesch RW, Chow LC, Beaulieu CF, et al. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: Secondary signs. Radiology 2002;224:764-768.
6. Saldinger PF, Reilly M, Reynolds K, et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J Gastrointest Surg 2000;4:233-237; discussion 238-9.
7. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-937.
8. Steinberg WM, Barkin J, Bradley EL 3rd, et al. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998;17:24-30.
9. Varadhachary GR, Tamm EP, Crane C, et al. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 2005;8:377-384.
10. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990;125:230-233.
11. Li H, Zeng MS, Zhou KR, et al. Pancreatic adenocarcinoma: The different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005;29:170-175.
12. Harris JP, Nelson RC. Abdominal imaging with multidetector computed tomography: State of the art. J Comput Assist Tomogr 2004;28(Suppl 1):S17-S19.
13. Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002;40:1263-1272.
14. Kalra MK, Maher MM, Mueller PR, Saini S. State-of-theart imaging of pancreatic neoplasms. Br J Radiol 2003;76:857-865.
15. Smith SL, Rajan PS. Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT. Clin Radiol 2004;59:26-38.
16. Ishiguchi T, Maruyama K, Fukatsu H, Ishigaki T. Radiologic diagnosis of pancreatic carcinoma. Semin Surg Oncol 1998;15:23-32.
17. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: Gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002;160:91-99.
18. Yachida S, Fukushima N, Nakanishi K, et al. Minute pancreatic adenocarcinoma presenting with stenosis of the main pancreatic duct. Pathol Int 2002;52:607-611.
19. Clarke DL, Thomson SR, Madiba TE, Sanyika C. Preoperative imaging of pancreatic cancer: A management-oriented approach. J Am Coll Surg 2003;196:119-129.
20. Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: Value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373-378.
21. Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998;170:1315-1322.
22. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168:1439-1443.
23. Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996;223:134-140.
24. Friess H, Kleeff J, Silva JC, et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998;186:675-682.
25. Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J Gastrointest Surg 1997;1:236-243; discussion 243-244.
26. Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325-337.
27. Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: A meta-analysis. J Comput Assist Tomogr 2005;29:438-445.
28. Rumstadt B, Schwab M, Schuster K, et al. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J Gastrointest Surg 1997;1:245-250.
29. Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr. MDCT in pancreatic adenocarcinoma: Prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004;182:419-425.
30. Reddy KR, Levi J, Livingstone A, et al. Experience with staging laparoscopy in pancreatic malignancy. Gastrointest Endosc 1999; 49(4 Pt 1):498-503.
31. Jones EC, Chezmar JL, Nelson RC, Bernardino ME. The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol 1992;158:535-539.
32. Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:227-251.
33. Roche CJ, Hughes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol 2003;180:475-480.
34. Acton PD, Zhuang H, Alavi A. Quantification in PET. Radiol Clin North Am 2004;42:1055-1062, viii.
35. Nichols MT, Russ PD, Chen YK. Pancreatic imaging: Current and emerging technologies. Pancreas 2006;33:211-220.
36. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979-2985.
37. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: Its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998;11:437-443.
38. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344-1348.
39. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727-1735.
40. Keogan MT, Tyler D, Clark L, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 1998;171:1565-1570.
41. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771-777.
42. Ho CL, Dehdashti F, Griffeth LK, et al. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996;20:363-369.
43. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345-352.
44. Klever P, Bares R, Fass J, et al. PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 1992;340:1158-1159.
45. Stollfuss JC, Glatting G, Friess H, et al. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation. Radiology 1995;195:339-344.
46. Rose DM, Delbeke D, Beauchamp RD, et al. 18 Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-737; discussion 737-8.
47. Sendler A, Avril N, Helmberger H, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: Diagnostic limitations. World J Surg 2000;24:1121-1129.
48. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784-1791.
49. Nakamoto Y, Higashi T, Sakahara H, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999;54:248-252.
50. Nishiyama Y, Yamamoto Y, Yokoe K, et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005;19:491-497.
51. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194-199.
52. Yokoyama Y, Nagino M, Hiromatsu T, et al. Intense PET signal in the degenerative necrosis superimposed on chronic pancreatitis. Pancreas 2005;31:192-194.
53. Goh BK, Tan YM, Chung YF. Utility of fusion CT-PET in the diagnosis of small pancreatic carcinoma. World J Gastroenterol 2005;11:3800-3802.
54. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/ computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235-243.
55. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-1442.
56. Magnani JL, Brockhaus M, Smith DF, et al. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 1981;212:55-56.
57. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10(Suppl 4):145-149.
58. Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988;3:61-66.
59. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987;92:60-67.
60. Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100-2108.
61. Pasquali C, Sperti C, D'Andrea AA, et al. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer. Pancreas 1987;2:34-37.
62. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-955; discussion 955-6.
63. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-5492.
64. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253-259.
65. Egawa S, Takeda K, Fukuyama S, et al. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004;28:235-240.
66. Riker A, Libutti SK, Bartlett DL. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 1997;6:157-169.
67. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-479.
68. Cerwenka H, Aigner R, Quehenberger F, et al. Preoperative differential diagnosis of benign and malignant pancreatic lesions-the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA. Hepatogastroenterology 1997;44:1117-1121.
69. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-491.
70. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-446.
71. Li Z, Sclabas GM, Peng B, et al. Overexpression of synucleingamma in pancreatic adenocarcinoma. Cancer 2004;101:58-65.
72. Sipos B, Hahn D, Carceller A, et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong upregulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004;45:226-236.